YAP1 overexpression
|
HCC
|
YAP1 overexpression
|
HCC
|
sorafenib + CA3 Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks (New D)
|
sorafenib + CA3 Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks - (New D)
|
YAP1 overexpression
|
HER2 Positive Breast Cancer
|
YAP1 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib Sensitive: C3 – Early Trials
|
trastuzumab + lapatinib Sensitive: C3 – Early Trials
|
YAP1 overexpression
|
HER2 Positive Breast Cancer
|
YAP1 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|